SCYX has 36-month beta value of 1.65. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SCYX is 37.16M, and currently, short sellers hold a 1.73% ratio of that float. The average trading volume of SCYX on June 13, 2025 was 137.55K shares.
SCYX) stock’s latest price update
Scynexis Inc (NASDAQ: SCYX)’s stock price has dropped by -7.08 in relation to previous closing price of 0.88. Nevertheless, the company has seen a loss of -7.19% in its stock price over the last five trading days. globenewswire.com reported 2025-05-28 that JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that patient dosing has resumed in the Phase 3 MARIO study, which is an innovative study to investigate oral ibrexafungerp as a potential step-down antifungal therapy following IV echinocandin for invasive candidiasis, a life-threatening infection. The study had been on hold due to concerns about potential cross-contamination in light of draft U.S. Food and Drug Administration (FDA) guidance regarding manufacturing a non-antibiotic beta-lactam (ezetimibe) at the same site as ibrexafungerp. The study has resumed following the manufacture of new clinical supplies at another site and the lifting of the clinical hold by the FDA. If the study is successful and approval for this indication is granted by the FDA, it will give healthcare providers the opportunity to step-down their patients to a non-azole oral therapy that retains the Mechanism of Action (glucan synthase inhibition) of the IV-only echinocandins, which are the gold standard for treatment of invasive Candida infections. SCYNEXIS’s position is that the dosing of this first new patient triggers a $10 million payment from partner GSK, with another $20 million payment to be triggered by the six-month anniversary of dosing. As previously disclosed, there is a disagreement between SCYNEXIS and GSK regarding the resumption of the MARIO Study and GSK’s responsibility for paying these milestones. SCYNEXIS is working to resolve the disagreement.
SCYX’s Market Performance
SCYX’s stock has fallen by -7.19% in the past week, with a monthly drop of -14.84% and a quarterly drop of -4.23%. The volatility ratio for the week is 4.91% while the volatility levels for the last 30 days are 8.51% for Scynexis Inc The simple moving average for the past 20 days is -3.95% for SCYX’s stock, with a -28.81% simple moving average for the past 200 days.
Analysts’ Opinion of SCYX
Many brokerage firms have already submitted their reports for SCYX stocks, with Guggenheim repeating the rating for SCYX by listing it as a “Buy.” The predicted price for SCYX in the upcoming period, according to Guggenheim is $25 based on the research report published on January 22, 2021 of the previous year 2021.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see SCYX reach a price target of $30. The rating they have provided for SCYX stocks is “Overweight” according to the report published on January 06th, 2021.
Needham gave a rating of “Buy” to SCYX, setting the target price at $5 in the report published on July 11th of the previous year.
SCYX Trading at -9.23% from the 50-Day Moving Average
After a stumble in the market that brought SCYX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.10% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SCYX starting from Federated Hermes Kaufmann Fund, who proposed sale 4,709 shares at the price of $1.23 back on Dec 18 ’24. After this action, Federated Hermes Kaufmann Fund now owns shares of Scynexis Inc, valued at $5,792 using the latest closing price.
Federated Hermes Kaufmann Smal, the 10% Owner of Scynexis Inc, proposed sale 128,957 shares at $1.23 during a trade that took place back on Dec 18 ’24, which means that Federated Hermes Kaufmann Smal is holding shares at $158,617 based on the most recent closing price.
Stock Fundamentals for SCYX
Current profitability levels for the company are sitting at:
- -15.26 for the present operating margin
- 1.0 for the gross margin
The net margin for Scynexis Inc stands at -11.42. The total capital return value is set at -0.61. Equity return is now at value -43.47, with -29.10 for asset returns.
Based on Scynexis Inc (SCYX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -11.04. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -28.79.
Currently, EBITDA for the company is -18.58 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 11.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.83.
Conclusion
To put it simply, Scynexis Inc (SCYX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
